Literature DB >> 34123949

Spinal Cord Compression Secondary to a Spontaneous Spinal Haematoma in a Patient Newly Treated with Rivaroxaban.

Javier Guerrero-Niño1, Sara De Cesaris1, Xavier Jannot2, Noel Lorenzo-Villalba2.   

Abstract

A 74-year-old patient anticoagulated with rivaroxaban for chronic atrial fibrillation presented to the emergency department with acute lumbar pain with progressive weakness of the lower limbs and inability to stand up. No previous trauma was reported. Neurological examination was consistent with a complete spinal cord syndrome at the level of T6. Magnetic resonance imaging showed the presence of spinal cord compression associated with signs of extensive intramedullary inflammation secondary to a haematoma. The patient underwent thoracic laminectomy with evacuation of an intradural haematoma. No intraoperative complications were described, but no clinical improvement had been achieved 15 days after the surgical intervention. LEARNING POINTS: Apixaban could be preferred as the first choice for direct oral anticoagulation (DOAC) in older patients.DOACs can have important side effects even if the switch from vitamin K antagonist to this group is correctly carried out. © EFIM 2021.

Entities:  

Keywords:  Rivaroxaban; anticoagulation; complete flaccid paraplegia; major bleeding

Year:  2021        PMID: 34123949      PMCID: PMC8191348          DOI: 10.12890/2021_002593

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


  9 in total

1.  Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry.

Authors:  Jan Beyer-Westendorf; Kati Förster; Sven Pannach; Franziska Ebertz; Vera Gelbricht; Christoph Thieme; Franziska Michalski; Christina Köhler; Sebastian Werth; Kurtulus Sahin; Luise Tittl; Ulrike Hänsel; Norbert Weiss
Journal:  Blood       Date:  2014-05-23       Impact factor: 22.113

2.  A practice tool for the new oral anticoagulants.

Authors:  Anne Massicotte
Journal:  Can Pharm J (Ott)       Date:  2014-01

3.  American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.

Authors: 
Journal:  J Am Geriatr Soc       Date:  2019-01-29       Impact factor: 5.562

4.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.

Authors:  S Schulman; C Kearon
Journal:  J Thromb Haemost       Date:  2005-04       Impact factor: 5.824

5.  Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).

Authors:  Shaun G Goodman; Daniel M Wojdyla; Jonathan P Piccini; Harvey D White; John F Paolini; Christopher C Nessel; Scott D Berkowitz; Kenneth W Mahaffey; Manesh R Patel; Matthew W Sherwood; Richard C Becker; Jonathan L Halperin; Werner Hacke; Daniel E Singer; Graeme J Hankey; Gunter Breithardt; Keith A A Fox; Robert M Califf
Journal:  J Am Coll Cardiol       Date:  2013-12-04       Impact factor: 24.094

6.  Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events.

Authors:  Steffany N Nguyen; Melanie C Ruegger; Eric Salazar; Diane Dreucean; Alexandra W Tatara; Kevin R Donahue
Journal:  J Pharm Pract       Date:  2021-04-12

7.  Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

Authors:  Sophie Testa; Cristina Legnani; Emilia Antonucci; Oriana Paoletti; Claudia Dellanoce; Benilde Cosmi; Vittorio Pengo; Daniela Poli; Rossella Morandini; Roberto Testa; Armando Tripodi; Gualtiero Palareti
Journal:  J Thromb Haemost       Date:  2019-05-26       Impact factor: 5.824

8.  Spontaneous cervical epidural hematoma: Insight into this occurrence with case examples.

Authors:  Brian Fiani; Ryan Jarrah; Nicholas J Fiani; Juliana Runnels
Journal:  Surg Neurol Int       Date:  2021-03-02

Review 9.  Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1.

Authors:  Hans-Christoph Diener; James Aisenberg; Jack Ansell; Dan Atar; Günter Breithardt; John Eikelboom; Michael D Ezekowitz; Christopher B Granger; Jonathan L Halperin; Stefan H Hohnloser; Elaine M Hylek; Paulus Kirchhof; Deirdre A Lane; Freek W A Verheugt; Roland Veltkamp; Gregory Y H Lip
Journal:  Eur Heart J       Date:  2017-03-21       Impact factor: 29.983

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.